AG真人官方

Niagen Bioscience to Present at Canaccord Genuity鈥檚 45th Annual Growth Conference

LOS ANGELES--(BUSINESS WIRE)-- (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity鈥檚 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston.

Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 12, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit .

Mr. Fried and Mr. Pamir will also hold one-on-one meetings with institutional investors throughout the conference. To arrange a meeting, please visit the conference website or contact your CG representative.

A replay of the fireside chat webcast will be available on the Niagen Bioscience Investor Relations website, , following the event.

For additional information on Niagen Bioscience, visit .

About Niagen Bioscience:

(NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience^鈩� is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There鈥檚 a better way to age.

At the heart of its clinically proven product portfolio is Niagen^庐 (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company鈥檚 consumer supplement, Tru Niagen^庐, the number one NAD+ boosting oral supplement in the United States^鈥� (available at ), and Niagen Plus^鈩�, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.

Niagen Bioscience鈥檚 robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at , where copies of press releases, news, and financial information are regularly published.

^鈥�Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).

View source version on businesswire.com:

Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310.405.5227

[email protected]

Niagen Bioscience Investor Relations Contact:

ICR, LLC

Reed Anderson

(646) 277-1260

Stephanie Carrington

(646) 277-1282

[email protected]

Source: Niagen Bioscience, Inc